Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal SHP611 in late infantile metachromatic leukodystrophy with matched external control
2024-514402-31-00Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2019
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 2, open-label trial of cebsulfase alfa in metachromatic leukodystrophy (MLD) (7 arms), sponsored by Takeda. Primary endpoint: Time to loss of locomotion or death in Group A. Started Sep 2019; status: completed.
02
Drugs
cebsulfase alfa
03
Conditions
metachromatic leukodystrophy (MLD)
Beyond the preview
Go deeper on 2024-514402-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514402-31-00.